United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $469.89, for a total value of $3,900,087.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $17,283,024.09. This represents a 18.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Stock Down 0.8%

NASDAQ UTHR opened at $471.99 on Friday. The firm has a market cap of $20.32 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 2.47 and a beta of 0.84. The company’s 50 day moving average is $486.53 and its 200-day moving average is $406.79. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business earned $6.39 EPS. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth about $29,000. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 46 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics in the third quarter worth approximately $44,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright raised their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group lifted their price objective on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company boosted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.